ArticlePloS one2025
Lobectomy versus sublobar resection on survival in patients with stage T1-2N0M0 small cell lung cancer.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Increased rates of surgical resection of early-stage small cell lung cancer in a single-institution cohort.Journal of thoracic disease · 2026Article
- Surgery versus chemoradiotherapy in patients with stage T1-2N0M0 small cell lung cancer: a retrospective cohort study.Journal of cardiothoracic surgery · 2026Article
- [New Landscape in the Treatment of Limited-stage Small Cell Lung Cancer: From Conventional Chemoradiotherapy to Latest Advances in Precision Medicine].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- Chemoradiotherapy versus radiotherapy in patients with stage T1-2N0M0 small cell lung cancer: a retrospective cohort study.BMC pulmonary medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare survival outcomes of lobectomy versus sublobar resection in patients diagnosed with stage T1-2N0M0 small cell lung cancer (SCLC). MATERIALS AND
methodsA comprehensive retrospective analysis was conducted using data from the Surveillance, Epidemiology, and End Results database. The Kaplan-Meier method was utilized to estimate cancer-specific survival (CSS) and overall survival (OS) between stage T1-2N0M0 SCLC patients undergoing sublobar resection and those receiving lobectomy.
resultsA total of 185 patients were included in the analysis, with 64 undergoing sublobar resection and 121 receiving lobectomy. Before propensity score matching, lobectomy was associated with significantly better CSS (hazard ratio [HR] =, 95% confidence interval [CI]: 0.32, P = 0.006) and OS (HR =, 95% CI: 0.39, P = 0.005) compared to sublobar resection. Multivariable Cox regression analysis confirmed that lobectomy was an independent predictor of improved CSS (HR =, 95% CI: 0.24, P = 0.003) and OS (HR =, 95% CI: 0.36, P = 0.013). After propensity score matching, the differences in CSS (HR =, 95% CI: 0.36, P = 0.177) and OS (HR =, 95% CI: 0.46, P = 0.234) between the two surgical approaches were not statistically significant.
conclusionLobectomy may offer improved survival outcomes compared to sublobar resection in patients with stage T1-2N0M0 SCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.